Mimetogen began operations in October 2005, developing the use of peptidomimetics as novel approaches to treat diseases with high unmet medical needs. The underlying technology has been developed at McGill University and the Lady Davis Institute for Medical Research in Montréal. The Company is currently developing novel therapeutic approaches for ophthalmic indications including dry eye syndrome, glaucoma and other degenerative diseases of the retina. Mimetogen also possesses a pipeline of validated leads for non-ophthalmic indications (such as neurodegenerative disease and pain) that it plans to partner. Please visit www.mimetogen.com.

Related news:

• Mimetogen Pharmaceuticals Completes Key Equity Financing
• Medwell Capital Announces $2 Million Investment in Mimetogen Pharmaceuticals
• Mimetogen Pharmaceuticals Inc. Secures Seed Financing from MSBi Capital
• Mimetogen Pharmaceuticals Inc. Closes Series A Financing and Completes Exclusive Licensing Agreement with McGill University
• Medwell Capital Announces that Mimetogen Pharmaceutical Inc. Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease